Activity of Zosurabalpin and Comparator Antimicrobial Agents Tested Against Acinetobacter baumannii-calcoaceticus Complex (ABC) Isolates Collected Worldwide in 2024
Activity of Zosurabalpin and Comparator Antimicrobial Agents Tested Against Acinetobacter baumannii-calcoaceticus Complex (ABC) Isolates Collected Worldwide in 2024. Lead author: Joshua M. Maher, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1333
Activity of manogepix against surveillance yeast isolates collected from the United States in 2023
Activity of manogepix against surveillance yeast isolates collected from the United States in 2023. Lead author: Marisa L. Winkler, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1195
In Vitro Antibacterial Spectrum and Activity of Tebipenem Against Enterobacterales Clinical Isolates Causing Urinary Tract and Bloodstream Infections in the United States and United Kingdom in 2023-2024
In Vitro Antibacterial Spectrum and Activity of Tebipenem Against Enterobacterales Clinical Isolates Causing Urinary Tract and Bloodstream Infections in the United States and United Kingdom in 2023-2024. Lead authors: R Kapoor, TB Doyle, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1214
Geographic distribution, MIC testing, and susceptibility rates of Candida auris isolates collected in the United States since 2014
Geographic distribution, MIC testing, and susceptibility rates of Candida auris isolates collected in the United States since 2014. Lead author: Marisa L. Winkler, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1196
A 10-year Trend on Antimicrobial Resistance of Pseudomonas aeruginosa from United States Medical Centers: Results from the INFORM Surveillance Program (2015–2024)
A 10-year Trend on Antimicrobial Resistance of Pseudomonas aeruginosa from United States Medical Centers: Results from the INFORM Surveillance Program (2015–2024). Lead author: Helio S. Sader, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1313
Five-year trend analysis of carbapenem-resistant Enterobacterales, including isolates carrying metallo-β-lactamase genes in United States, Europe and adjacent regions during 2020–2024
Five-year trend analysis of carbapenem-resistant Enterobacterales, including isolates carrying metallo-β-lactamase genes in United States, Europe and adjacent regions during 2020–2024. Lead author: Mariana Castanheira, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1279
In Vitro Activity of Cefiderocol against Resistant Subsets of Pseudomonas aeruginosa Collected from United States Hospitals during 2020–2024
In Vitro Activity of Cefiderocol against Resistant Subsets of Pseudomonas aeruginosa Collected from United States Hospitals during 2020–2024. Lead author: R. E. Mendes, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1287
Activity of Aztreonam-Avibactam and Comparators against Difficult-to-Treat Resistant (DTR) Enterobacterales from United States Medical Centers (2020–2024)
Activity of Aztreonam-Avibactam and Comparators against Difficult-to-Treat Resistant (DTR) Enterobacterales from United States Medical Centers (2020–2024). Lead author: Helio S. Sader, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1316
Gepotidacin activity against Escherichia coli and Klebsiella pneumoniae, including molecularly characterized ESBL- and carbapenemase-positive subsets causing urinary tract infections in United States Medical Centers (2023)
Gepotidacin activity against Escherichia coli and Klebsiella pneumoniae, including molecularly characterized ESBL- and carbapenemase-positive subsets causing urinary tract infections in United States Medical Centers (2023). Lead author: R. E. Mendes, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1203
Antimicrobial Activity of Aztreonam-Avibactam and Molecular Characterization of Enterobacterales Resistant to Ceftazidime-Avibactam and/or Meropenem-Vaborbactam from United States Medical Centers (2016–2024)
Antimicrobial Activity of Aztreonam-Avibactam and Molecular Characterization of Enterobacterales Resistant to Ceftazidime-Avibactam and/or Meropenem-Vaborbactam from United States Medical Centers (2016–2024). Lead author: Helio S. Sader, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1319
Performance of the VITEK 2 with Advance Expert System as a Fast Method for Determination of Antimicrobial Susceptibility Against 400 Enterobacterales Isolates from North America and Latin America (2022)
Performance of the VITEK 2 with Advance Expert System as a Fast Method for Determination of Antimicrobial Susceptibility Against 400 Enterobacterales Isolates from North America and Latin America (2022). Lead author: Michael D. Huband, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1697
Activity of Delafloxacin and Comparator Agents Against Bacterial Isolates from Patients with Diabetic Foot Infection in the United States and Europe (2017–2023)
Activity of Delafloxacin and Comparator Agents Against Bacterial Isolates from Patients with Diabetic Foot Infection in the United States and Europe (2017–2023). Lead author: Michael D. Huband, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1340
Antimicrobial susceptibility of S. maltophilia and B. cepacia species complex isolated from patients with pneumonia in United States hospitals (2022–2024)
Antimicrobial susceptibility of S. maltophilia and B. cepacia species complex isolated from patients with pneumonia in United States hospitals (2022–2024). Lead author: Helio S. Sader, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1320
Activity of aztreonam-avibactam against Enterobacterales isolated from patients with intra-abdominal infection from Europe, Asia, and Latin America (2020–2024)
Activity of aztreonam-avibactam against Enterobacterales isolated from patients with intra-abdominal infection from Europe, Asia, and Latin America (2020–2024). Lead author: Helio S. Sader, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1314
Activity of isavuconazole against contemporary Mucorales from a worldwide surveillance program
Activity of isavuconazole against contemporary Mucorales from a worldwide surveillance program. Lead author: Marisa L. Winkler, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1193
Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents Tested against Enterobacterales from European Hospitals Analysed by Infection Type (2022–2024)
Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents Tested against Enterobacterales from European Hospitals Analysed by Infection Type (2022–2024). Lead author: Helio S. Sader, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1317
Activity of aztreonam-avibactam tested against genetically characterized non-carbapenemase-producing carbapenem-resistant Enterobacterales
Activity of aztreonam-avibactam tested against genetically characterized non-carbapenemase-producing carbapenem-resistant Enterobacterales. Lead author: Mariana Castanheira, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1332
In vitro activity of gepotidacin and comparator agents against a collection of Escherichia coli and Klebsiella pneumoniae urine isolates from the United States during 2023
In vitro activity of gepotidacin and comparator agents against a collection of Escherichia coli and Klebsiella pneumoniae urine isolates from the United States during 2023. Lead author: S.J. Ryan Arends, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1174
Gepotidacin activity against Escherichia coli and Klebsiella pneumoniae, including molecularly characterized fluoroquinolone not susceptible subsets causing urinary tract infections in United States Medical Centers (2023)
Gepotidacin activity against Escherichia coli and Klebsiella pneumoniae, including molecularly characterized fluoroquinolone not susceptible subsets causing urinary tract infections in United States Medical Centers (2023). Lead author: R. E. Mendes, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1204
Activity of Aztreonam-Avibactam and Ceftazidime-Avibactam against Enterobacterales and Pseudomonas aeruginosa Causing Infections in Immunosuppressed Patients from United States Medical Centers (2019–2024)
Activity of Aztreonam-Avibactam and Ceftazidime-Avibactam against Enterobacterales and Pseudomonas aeruginosa Causing Infections in Immunosuppressed Patients from United States Medical Centers (2019–2024). Lead author: Helio S. Sader, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1315
In vitro Activity of Cefiderocol against Carbapenem-Nonsusceptible Acinetobacter baumannii-calcoaceticus Complex, Including Molecularly Characterized Clinical Isolates, Causing Infections in United States Hospitals (2020–2024)
In vitro Activity of Cefiderocol against Carbapenem-Nonsusceptible Acinetobacter baumannii-calcoaceticus Complex, Including Molecularly Characterized Clinical Isolates, Causing Infections in United States Hospitals (2020–2024). Lead author: R. E. Mendes, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1286
Activity of cefiderocol and comparator agents against carbapenem-resistant Enterobacterales, including molecularly characterized isolates recovered from United States hospitals in 2020–2024
Activity of cefiderocol and comparator agents against carbapenem-resistant Enterobacterales, including molecularly characterized isolates recovered from United States hospitals in 2020–2024. Lead author: Mariana Castanheira, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1278
In vitro activity of EL219 (SF001) and amphotericin B agents against a collection of Candida and Aspergillus isolates collected in 2024
In vitro activity of EL219 (SF001) and amphotericin B agents against a collection of Candida and Aspergillus isolates collected in 2024. Lead author: S.J. Ryan Arends, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1205
Activity of Tebipenem Against Enterobacterales, Including Molecularly Characterized Clinical Isolates Causing Urinary Tract and Bloodstream Infections from the United States in 2023
Activity of Tebipenem Against Enterobacterales, Including Molecularly Characterized Clinical Isolates Causing Urinary Tract and Bloodstream Infections from the United States in 2023. Lead authors: R Kapoor, TB Doyle, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1213
Activity of manogepix against mould isolates from the US collected in 2023
Activity of manogepix against mould isolates from the US collected in 2023. Lead author: Marisa L. Winkler, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1194
Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents against Stenotrophomonas maltophilia Isolates from Patients Hospitalized with Pneumonia in Europe, Latin America, and Asia (2020–2024)
Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents against Stenotrophomonas maltophilia Isolates from Patients Hospitalized with Pneumonia in Europe, Latin America, and Asia (2020–2024). Lead author: Helio S. Sader, presented at IDWeek 2025, Oct 21, Atlanta, GA, USA
Poster #P1318
Activity of cefiderocol against carbapenem-resistant and molecularly characterized Enterobacterales isolates causing infections in hospitals in Europe and adjacent regions (2020–2023)
Activity of cefiderocol against carbapenem-resistant and molecularly characterized Enterobacterales isolates causing infections in hospitals in Europe and adjacent regions (2020–2023). Lead author: Rodrigo E. Mendes, presented at ESCMID Global 2025, April 14, Vienna, Austria
Poster #E0721
Activity of omadacycline against multidrug-resistant and molecularly characterized Acinetobacter baumannii-calcoaceticus complex clinical isolates from United States hospitals (2020–2023)
Activity of omadacycline against multidrug-resistant and molecularly characterized Acinetobacter baumannii-calcoaceticus complex clinical isolates from United States hospitals (2020–2023). Lead author: Rodrigo E. Mendes, presented at ESCMID Global 2025, April 14, Vienna, Austria
Poster #P1314
Zosurabalpin (5 μg) disk diffusion quality control ranges using Clinical and Laboratory Standards Institute M23 Tier 1 and Tier 2 criteria
Zosurabalpin (5 μg) disk diffusion quality control ranges using Clinical and Laboratory Standards Institute M23 Tier 1 and Tier 2 criteria. Lead author: Michael D. Huband, presented at ESCMID Global 2025, April 14, Vienna, Austria
Poster #2545
Gepotidacin activity against and analysis of susceptibility to oral standard-of-care antibiotics for urinary tract infections caused by Escherichia coli and Klebsiella pneumoniae collected in Europe in 2023
Gepotidacin activity against and analysis of susceptibility to oral standard-of-care antibiotics for urinary tract infections caused by Escherichia coli and Klebsiella pneumoniae collected in Europe in 2023. Lead author: S. J. Ryan Arends, presented at ESCMID Global 2025, April 14, Vienna, Austria
Poster #P1216
Activity of gepotidacin against molecularly characterized β-lactamase-producing E. coli and K. pneumoniae isolates from patients with urinary tract infections in Europe and adjacent regions (2023)
Activity of gepotidacin against molecularly characterized β-lactamase-producing E. coli and K. pneumoniae isolates from patients with urinary tract infections in Europe and adjacent regions (2023). Lead author: Rodrigo E. Mendes, presented at ESCMID Global 2025, April 14, Vienna, Austria
Poster #P1217
Activity of cefiderocol against carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2023)
Activity of cefiderocol against carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2023). Lead author: Rodrigo E. Mendes, presented at ESCMID Global 2025, April 14, Vienna, Austria
Poster #P1351
Increase in blaNDM-1 among carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex clinical isolates collected in 2023 from U.S. and European medical centres
Increase in blaNDM-1 among carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex clinical isolates collected in 2023 from U.S. and European medical centres. Lead author: John H. Kimbrough, presented at ESCMID Global 2025, April 14, Vienna, Austria
Poster #P1273
Gepotidacin activity against E. coli and K. pneumoniae, including molecularly characterized fluoroquinolone not susceptible subsets causing urinary tract infections in Europe and adjacent regions (2023)
Gepotidacin activity against E. coli and K. pneumoniae, including molecularly characterized fluoroquinolone not susceptible subsets causing urinary tract infections in Europe and adjacent regions (2023). Lead author: Rodrigo E. Mendes, presented at ESCMID Global 2025, April 14, Vienna, Austria
Poster #P1216
Activity of cefiderocol against carbapenem-resistant Pseudomonas aeruginosa, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2023)
Activity of cefiderocol against carbapenem-resistant Pseudomonas aeruginosa, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2023). Lead author: Rodrigo E. Mendes, presented at ESCMID Global 2025, April 14, Vienna, Austria
Poster #P1349
The microbiological and clinical complexity of infections in patients with treatment-refractory Mycobacterium avium complex lung disease
The microbiological and clinical complexity of infections in patients with treatment-refractory Mycobacterium avium complex lung disease. Lead author: Timothy B. Doyle, presented at ESCMID Global 2025, April 13, Vienna, Austria
Poster #P0619
Antimicrobial activity of zosurabalpin against a diverse collection of aerobic and anaerobic bacterial and yeast isolates
Antimicrobial activity of zosurabalpin against a diverse collection of aerobic and anaerobic bacterial and yeast isolates. Lead author: JM Maher, presented at ESCMID Global 2025, April 13, Vienna, Austria
Poster #P2350
Echinocandin susceptibility patterns and genetic changes in nonsusceptible Candida glabrata with non-hotspot FKS alterations
Echinocandin susceptibility patterns and genetic changes in nonsusceptible Candida glabrata with non-hotspot FKS alterations. Lead author: Marisa L. Winkler, presented at ESCMID Global 2025, April 12, Vienna, Austria
Poster #P2889
Activity of manogepix against a worldwide collection of yeast isolates from 2023
Activity of manogepix against a worldwide collection of yeast isolates from 2023. Lead author: Marisa L. Winkler, presented at ESCMID Global 2025, April 12, Vienna, Austria
Poster #P2891
Phylogenomics reveals patterns of azole activity against Aspergillus section Nigri clinical isolates.
Phylogenomics reveals patterns of azole activity against Aspergillus section Nigri clinical isolates. Lead author: John H. Kimbrough, presented at ESCMID Global 2025, April 12, Vienna, Austria
Poster #P2900
In vitro Activity of Gepotidacin Tested Against Molecularly Characterized Escherichia coli Isolates Responsible for Urinary Tract Infections in the US (2019–2022)
In vitro Activity of Gepotidacin Tested Against Molecularly Characterized Escherichia coli Isolates Responsible for Urinary Tract Infections in the US (2019–2022). Lead author: Rodrigo E. Mendes, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1060
Activity of aztreonam-avibactam against Enterobacterales isolated from patients with intra-abdominal infection from United States medical centers (2019–2023)
Activity of aztreonam-avibactam against Enterobacterales isolated from patients with intra-abdominal infection from United States medical centers (2019–2023)Lead author: Helio S. Sader, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1081
In vitro Activity of Gepotidacin against Klebsiella pneumoniae, Including Molecularly Characterized ESBL and Carbapenemase Positive Subsets Causing Urinary Tract Infections in the United States (2019–2022)
In vitro Activity of Gepotidacin against Klebsiella pneumoniae, Including Molecularly Characterized ESBL and Carbapenemase Positive Subsets Causing Urinary Tract Infections in the United States (2019–2022). Lead author: Rodrigo E. Mendes, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1059
In vitro Activity of Gepotidacin against Klebsiella pneumoniae, Including Molecularly Characterized Fluoroquinolone Not Susceptible Subsets Causing Urinary Tract Infections in the United States (2019–2022)
In vitro Activity of Gepotidacin against Klebsiella pneumoniae, Including Molecularly Characterized Fluoroquinolone Not Susceptible Subsets Causing Urinary Tract Infections in the United States (2019–2022). Lead author: Rodrigo E. Mendes, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1061
In vitro Activity of Gepotidacin and Comparator Agents Against a Collection of Klebsiella pneumoniae Urine Isolates Collected from the United States during 2019–2022
In vitro Activity of Gepotidacin and Comparator Agents Against a Collection of Klebsiella pneumoniae Urine Isolates Collected from the United States during 2019–2022. Lead author: S. J. Ryan Arends, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #1062
Aztreonam-Avibactam Activity against Gram-negative Bacteria Isolated from Patients with Pneumonia from Europe, Asia, and Latin America (2021–2023)
Aztreonam-Avibactam Activity against Gram-negative Bacteria Isolated from Patients with Pneumonia from Europe, Asia, and Latin America (2021–2023). Lead author: Helio S. Sader, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1080
Antimicrobial Susceptibility of Enterobacterales Causing Infection in the Elderly: Focus on Aztreonam-Avibactam and Recently Approved β-Lactamase Inhibitor Combinations
Antimicrobial Susceptibility of Enterobacterales Causing Infection in the Elderly: Focus on Aztreonam-Avibactam and Recently Approved β-Lactamase Inhibitor
Combinations. Lead author: Helio S. Sader, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1082
Antimicrobial Activity of Aztreonam- Avibactam and Comparator Agents against a Large Collection of Stenotrophomonas maltophilia Isolates Collected in United States Medical Centers (2019–2023)
Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents against a Large Collection of Stenotrophomonas maltophilia Isolates Collected in United States Medical Centers (2019–2023). Lead author: Timothy B. Doyle, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1083
Antimicrobial Activity of Aztreonam- Avibactam and Other β-Lactamase Inhibitor Combinations Tested against Enterobacterales Isolates from Pediatric Patients from United States Medical Centers (2019–2023)
Antimicrobial Activity of Aztreonam-Avibactam and Other β-Lactamase Inhibitor Combinations Tested against Enterobacterales Isolates from Pediatric Patients from United States Medical Centers (2019–2023). Lead author: Helio S. Sader, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1084
Characterization of Enterobacter cloacae and Citrobacter freundii species complex isolates with decreased susceptibility to cephalosporins from United States hospitals and activity of aztreonam-avibactam and comparator agents (2019–2023)
Characterization of Enterobacter cloacae and Citrobacter freundii species complex isolates with decreased susceptibility to cephalosporins from United States hospitals and activity of aztreonam-avibactam and comparator agents (2019–2023). Lead author: Helio S. Sader, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1085
